AbbVie completes $8.7 billion Acquisition of Cerevel

On August 1, 2024, AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics. The deal closed after a merger review by the U.S. Federal Trade Commission.

A Compass Lexecon team led by Nathan Wilson supported counsel through the HSR process, developing and presenting economic evidence that showed the proposed merger would not harm competition while also aiding in the process of successfully complying with the FTC’s second request.

Nathan Wilson was supported by a team that included Erica Benton, Ian MacSwain, Allan Zhang, Ryan Dorow, Benjamin Rosenbaum, Iryna Iakusheva, Holly Chin, and Eleanor Lefgren.

Compass Lexecon worked closely with Debbie Feinstein and Matt Tabas of Arnold & Porter, and Michael Perry, Kristen Limarzi, and Matthew Parrott of Gibson, Dunn, & Crutcher.